Azurity Archives
News and events as they happenAzurity Pharmaceuticals announces the FDA Approval of XIFYRM™ (meloxicam injection) for the Management of Moderate-to-Severe Pain in Adults
FOR IMMEDIATE RELEASE Woburn, MA — June 10, 2025 — Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved XIFYRMTM (meloxicam injection) an IV non-steroidal anti-inflammatory drug (NSAID) that offers once daily dosing.
Azurity Pharmaceuticals Completes Acquisition of Covis Pharma
MEDIA ALERT: WOBURN, MA, March 14, 2025 – Azurity Pharmaceuticals (“Azurity”) announced today the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a wholly-owned subsidiary of Azurity.
AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF
AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII
MEDIA ALERT: WOBURN, Mass. December 11, 2024 – Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency…
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF
DANZITEN™ (nilotinib) tablets, THE FIRST AND ONLY NILOTINIB WITH NO MEALTIME RESTRICTIONS
MEDIA ALERT: WOBURN, Mass. Nov 14, 2024 – Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients with newly diagnosed Philadelphia chromosome positive…
